Since knockdown of DCLK-isoform2 resulted in enhanced CD8 + T cell activation and decreased pancreatic cancer cell viability—this study with spheroids suggested DCLK-isoform2 as a novel therapeutic target in PDAC (Chandrakesan et al., 2020). The gene discussed is DCLK1; the disease is pancreatic neoplasm.